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Abstract
Biosensing systems based on microneedles can overcome the stratum corneum 
of the skin, i. e. the outer natural barrier of the human body, without any pain and 
detect the target analytes directly in the interstitial fluid. Moreover, microneedle-
based devices (MNDs) can combine diagnostic sensing and therapeutic admin-
istration of drugs in one single tool. From this point of view, more than a painless 
door to the human body, a MND represents the a perfect example of theranostic 
instrument, since a single device could quantify the real value of a relevant biomol-
ecule, such as glucose, and accurately deliver a drug, the insulin, if needed. MNDs 
could be integrated on printed circuit boards, flexible electronics and microfluidic 
channels, thus allowing a continuous monitoring of the physiological parameters 
with very low invasiveness, together with sustained and localized administration 
of drugs. MNDs can be designed for very specific applications, from the detection 
of skin cancer to the monitoring of metabolic pathways. Moreover, several fabrica-
tion approaches have been introduced, from laboratories to large-scale production. 
Finally MNDs can be properly functionalized to enhance analytical performances.
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1. Introduction
A new type of biomedical devices was born when technologies and facilities for 
Micro and Nano Electro Mechanical Systems (MEMS and NEMS) fabrication have 
met medical and biological issues. These new kinds of biomedical devices are able 
to easily control physical and chemical parameters at a very small scale, down to 
nanomolar concentrations and nanometric sizes [1–3]. Moreover, the integration of 
such a device in wearable and/or mobile systems gave them popularity among com-
mercial devices. In this technological frame, Microneedles based devices (MNDs) 
were born. Their height is sufficiently large to overcome the outer natural barrier 
of the human body, the stratum corneum of the skin, but not enough to reach the 
nerves, resulting in a lack of pain [4]. Usually, MN height is ranging from 10 to 
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1000 μm, depending on the application and how deep in the epidermis is the spe-
cific target analyte. Then, MNs based devices act as an interface between the body 
of the patient and a biomedical device, whose applications can range from fluid 
extraction for ex-situ analysis to drug and gene delivery, from in situ diagnostic 
tools to targeted cell therapy [1–4]. Material, length, shape of the body and the tip 
of the MNs drastically vary depending on the application [2, 3] and the fabrication 
technology, according to new needs and challenges. Biosensing systems based on 
MNs have to overcome the stratum corneum without pain and to detect the target 
Figure 1. 
(A) Sketch of different MNDs for sensing purposes together with their working conditions into the human 
skin. Starting from the right, they are characterized by the locus of probe-analyte interaction: Swelling bulk 
MNs sensors (BMNDs), where probe-analyte interaction is inside the volume of MN; hollow MNs sensors 
(HMNDs), where a small material sampling of ISF is analyzed on or offline; coated MNs sensors (CMNDs), 
whose surface is the locus of the interaction between analytes and bioprobes; planar MNs sensors (PMNDs), 
where the probe–analyte interaction is on a specific zone of a flat MNs surface. (B) some configurations for 
MNs for drugs delivery: (from left) hollow MNs present a inner cavities to immediately administration of high 
dose and high MW drugs; soluble and hybrid MNs for fast administration with a high doses and medium MW; 
coated MNs for fast administration of low doses and any MW; swelling MNs for very slow administration of 
high doses of smaller molecules. Reproduced with permission of Ref. [8].
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analytes directly in the interstitial fluid. In those cases, more than a strategy could 
be used: the functionalization of the surface of MNs with a specific probe, realizing 
a coated MND [5], the trapping of probe molecules into a swelling material [6] 
or the extraction of fluids and the analysis into a microfluidic system [7] are only 
some examples. In Figure 1A a sketch of different MNDs for sensing purposes is 
shown.
Moreover, microneedle-based devices (MNDs) can combine diagnostic  
sensing and therapeutic administration of drugs in one single tool. From this point 
of view, more than a painless door to the human body, a MND represents the a 
perfect example of theranostic instrument, since a single device could quantify 
the real value of a relevant biomolecule, such as glucose, and accurately deliver 
a drug, the insulin, if needed. MNDs are particularly interesting as simple drug 
administration tools, too. In fact, the transdermal route for drug administration 
is a very fascinating way, not only for the very low invasiveness and the easiness 
of self-administration, but also for the absence of first pass metabolism. However, 
the intercellular lipid matrix of the epidermis consists of ceramides, free fatty 
acids, and cholesterol, a complex mixture of neutral lipids arranged as bilayers 
with hydrophobic chains facing each other (lipophilic bimolecular leaflet) [9]. 
Transdermal delivery works only for lipophilic uncharged drugs with low MW 
(<500 Da), which need low dose and continuous delivery. Moreover, components, 
formulations and drugs must be non-irritating and non-sensitizing. MNs can 
be used with both lipophilic and hydrophilic formulations, both charged and 
uncharged drugs, both small and oversized molecules.
For all these cases, MN configurations are illustrated in Figure 1B, where the 
possibility to use solving or hybrid soluble/insoluble MNs are considered.
MNDs could be integrated on printed circuit boards, flexible electronics and 
microfluidic channels, thus allowing a continuous monitoring of the physiologi-
cal parameters with very low invasiveness, together with sustained and localized 
administration of drugs. MNDs can be designed for very specific applications, from 
the detection of skin cancer to the monitoring of metabolic pathways.
2. Microneedles array fabrication
Technologies, skills and facilities for Micro and Nano Electro Mechanical 
Systems (MEMS and NEMS) fabrication are the key elements for the development 
of new biomedical devices [1–3, 10]. Fabrication methods for Microneedles (MNs) 
strongly depend on the MNs shape, tip model, length, density of the MNs matrix, 
and the material of which they are made of.
Moreover, structural characteristics of the MNs matrix in turn depend on the 
specific application considered [11]. In fact, MNDs are exploited in fluid extraction 
[12] and in-situ diagnosis of diseases [13], in drug and gene delivery strategies [1, 11], 
in cell therapy [3] and so on.
At first, Silicon and silicon-based nanostructured materials, such as porous 
silicon, were largely employed in MNDs fabrication due to the well-established func-
tionalization chemistry protocols and fabrication techniques, extenseively used in 
microelectronics, which simplified the integration into more complex systems [14]. 
However, silicon revealed to be a non-biocompatible material, due to its fragility and 
to the local inflammations (silicosis) it could provoke; for this reason its use has been 
limited in cell applications [15].
To overcome limitations on the use of silicon, polymers have been extensively 
proposed as alternative materials in many applications. Poly Dimethyl Siloxane 
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Figure 2. 
Main fabrication strategies for MNs fabrication. Replica molding [16] centrifugal lithography [17] 
photolithography [18] drawing lithography [19].
(PDMS) is one of the most used materials in microfluidics to design biomedical 
devices, due to its well-known biological compatibility [16]. Usually, PDMS is 
employed as mold to fabricate MNDs by replica molding (see Figure 2). In case of 
PDMS molding, the fabrication involves the following steps: female PDMS mold 
fabrication by means of standard photolithography or laser drilling; patterned 
MNs in PDMS mold filling with liquid polymers in vacuum conditions; curing of 
the polymers by temperature and/or UV exposure; mold removal; eventually, an 
additional curing step [16]. Biodegradable polymers have been largely employed 
in MNDs for drugs delivery application [20–24], but the biodegradability is not 
required for biosensing.
A direct method for MNDs fabrication is the so-called drawing lithography [19]. 
Drawing lithography is a fabrication method, which does not need light irradiation 
and a mask, since it is based on the use of a thermosetting polymer directly drawn 
from a 2D solid surface (see Figure 2). In drawing lithography, commercial pho-
toresist is usually spin coated or drop casted onto the substrate and cooled down. 
Drills are fixed in an array on a PDMS frame and used as pillars contacted with the 
photoresist. Conical-shaped bridges between the substrate and the pillars appear 
when their relative distance is increased by drawing (elongation). The bridges are 
cured to generate a rigid structure. Finally, the separation of the bridges produces 
the desired MND.
However, drawing method lacks in flexibility and the curing at high tem-
perature of the polymers encapsulating biopharmaceutical molecules can cause 
their denaturation or inactivation. In fact, MNDs encapsulating drugs or bio-
probes must be fabricated in a controlled environment to preserve the biological 
activity.
The increasing demand for simple methods that preserve the biological activity 
by utilizing the natural properties of polymers has conducted to the idea of cen-
trifugal lithography [17]. In [17], centrifugal lithography was used for the fabrica-
tion of MNDs in a single centrifugation, by exploiting the self-shaping properties 
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of hyaluronic acid (HA). Briefly, fabrication involves the following steps: HA drops 
encapsulating drugs molecules are casted onto the substrate; centrifugal force is 
applied under refrigerated conditions (4°C) to the droplets in order to shape in 
hourglass microstructures; finally, the mirroring shapes are separated to form MNs. 
Also in the case of HA, drug delivery is successfully obtained, but biosensing is 
unavailable due to its biodegradability.
On the other hand, hydrogel polymers are very attractive materials for MNDs 
and, generally, for biomedical devices, since a hydrated gel provides near physi-
ological conditions. These gels are excellent encapsulation matrices for biological 
probes, such as enzymes and peptides [18, 20, 25, 26]. Moreover, the standard 
photolithographic processes can be employed to fabricate micrometric devices 
based on polymeric hydrogels [materials] (Figure 2). In [6, 18, 27, 28], authors 
proposed procedures of standard direct photolithography, where a mixture of 
Poly(ethylene glycol) diacrylate (PEGDA) and a commercial photoinitiator were 
used as an ordinary photoresist, without any etching step being required. In fact, 
PEGDA is a biocompatible polymer that solidifies at room temperature in pres-
ence of a photoinitiator after exposure to ultraviolet (UV) light for few seconds. 
In case of photolithographic process, the fabrication involves the following steps: 
the liquid photosensitive polymeric mixture is casted onto a UV-transparent sub-
strate and exposed to ultraviolet radiation, in order to fabricate the MNDs base; 
a vessel is fulfilled with a second quantity of liquid mixture and the MNDs base 
is put on; a second exposure through a mask, whose pattern is an array of holes, 
is applied; finally the structure is developed by simply washing in deionized 
water. The PEGDA mixture can be customized to encapsulate a variety of drugs 
or sensing probes as biological molecules or inorganic nanoparticles [29–31].
Comparing the fabrication methods, all produced MNs have demonstrated high 
quality in indentation proof and a good grade of reproducibility, with some critical 
issues during the mold removal step in replica molding method.
Figure 3. 
The photolithographic methods offer a wide range of solutions for MNDs. Changing time exposure and/or 
photolithographic mask several configurations and arrays of MNs for both therapeutics and biosensing can 
be fabricated. From above: Mask type 1 (simple circle) enables MNs with several heights depending on time 
exposure; mask type 2 (ring) enables hollow MNs with height and closure depending on time exposure; mask 
type 3 (mismatched concentric ring) enables in one only exposure hollow MNs with a lateral oblique aperture, 
which is smaller as the exposure time increases.
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Finally, we highlight that the photolithographic approach allows the fabrication 
of MNDs for a wide range of applications. In fact, this process allows the design of 
a wide range of MN types with different shape, length and tip, simply by adjusting 
the exposure parameters or shape photolithographic masks [18, 28]. In Figure 3, 
the whole range of possibilities enabled by photolithographic method are sum-
marized: mask type 1 (simple circle) enables MNs with several heights depending 
on time exposure; mask type 2 (ring) enables hollow MNs with height and closure 
depending on time exposure; mask type 3 (mismatched concentric ring) enables in 
a single exposure the fabrication of hollow MNs with a lateral oblique aperture as 
in hypodermic syringes. Also in this case, lateral aperture is smaller as the exposure 
time increases.
3. Drug delivery patches
MNs represent actually a flexible technological platform, which enables innova-
tive diagnostic solutions and breakthrough therapeutic issues in biomedicine [1–3]. 
First, finding a painless alternative to hypodermic injections has driven researchers 
to the development of MNDs. In fact, belonephobia, which is the unreasonable fear 
of needles, affects up to 10% of the population and has implications for treatment 
and follow up, especially in the pediatric patients [32]. In reverse, the sensation 
caused by MNs has proved to be statistically indistinguishable from a smooth sur-
face and the pain caused by a hypodermic needle has been perceived substantially 
more than MNs [4]. Moreover, as previously stated, the transdermal route for drug 
administration is a very fascinating way, not only for the very low invasiveness and 
the easiness of self-administration, but also for the absence of first pass metabolism. 
However, the intercellular lipid matrix of the epidermis consists of ceramides, 
free fatty acids, and cholesterol, a complex mixture of neutral lipids arranged as 
bilayers with hydrophobic chains facing each other (lipophilic bimolecular leaflet) 
[9]. Transdermal delivery works only for lipophilic uncharged drugs with low 
MW (<500 Da), which need low dose and continuous delivery. Moreover, compo-
nents, formulations and drugs must be non-irritating and non-sensitizing. MNs 
can be used with both lipophilic and hydrophilic formulations, both charged and 
uncharged drugs, both small and oversized molecules. In fact, currently, interesting 
MNDs are involved in clinical trials both for some topical applications, as analgesic 
compounds, anti-inflammatory or anesthetic drugs, and for some traditional 
systemic drugs, such as anticancer drugs, vaccines, insulin or hormones [33].
Among the topical applications, MNDs can replace very invasive methods 
for warts therapy, such as electrocautery and cryotherapy. A MND developed by 
Ryu et al. for warts treatment resulted to be innovative and effective [34]. In this 
study, quite 40 patients with wart lesions were enrolled and referred less pain than 
cryotherapy, as well as more tolerability with respect to electrocautery. Other skin 
diseases have been treated by means of MNDs, as melasma in [35], where authors 
fabricated biocompatible polymeric MNs based on methacrylic acid and polyvinyl 
pyrrolidone (PVP) to locally administer tranexamic acid, an innovative molecule 
that inhibits excessive melanin production by acting on melanocytes.
Acne vulgaris is another common inflammatory skin disease, affecting both 
physiologically and psychologically on patients. Barrier properties of skin strongly 
limit the usual antibiotic drug creams used to cure acne, but the use of MNs can 
overcome this limits, by using a reactive oxygen species–responsive [36]. In some 
in-vivo studies, MNDs for anti-acne therapy demonstrated bioresponsivity and effi-
ciency to prevent bacterial growth. Finally, among the local administration taking 
advantage of MNs, the treatment of cornea diseases must be quoted. In particular, 
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using dissolving polymeric microneedles to deliver besifloxacin to the cornea, a 
significant improvement in besifloxacin deposition and permeation were proven 
after only 5 minutes of application [37].
On the other hand, also administration of systemic drugs by means of MNDs 
showed good results in effectiveness, safe and economic efficiency as disposal 
devices. A wide range of molecules has been proven to be compatible with MNDs 
and each category of drug showed specific advantages compared to the use of oral 
or hypodermic administration.
First of all, vaccine delivery is probably the most involved health issue in MN 
technology, due to the large number of people involved each year. Nguyen and Park 
recently reviewed MNDs enrolled in human studies and reported the progress of 
MNDs in the clinical trials [38]. Finally, the use of MNs in therapy for clinical vac-
cine was recognized as very important, but further tests are recommended.
When MNDs is used to deliver vaccines based on DNA, some studies show that 
the gene expression is improved with respect to the results of conventional hypo-
dermic injection. Consequently, the use of MNs to administrate DNA based vaccine 
results in an improvement of the immune responses [38, 39]. In [39], Authors 
hypothesized that the improvement of the immune response by delivering DNA 
vaccine by means of MNs could be due to the enhancement of the protein expres-
sion of the encoded gene.
Another important issue of vaccine administration improved by MNDs is the 
stability of the active ingredients into dissolving or swellable MNs. Encapsulation of 
inactivated polio vaccine (IPV) into dissolving MNs gains a better thermal stability 
with respect to that of the conventional liquid formulation of IPV [40]. The greater 
thermostability of the MN patches can generally enable a mass distribution with less 
constrains on cold chain storage resulting in a great reduction of costs, since global 
vaccination strategies require large immunization coverage. Moreover, new MNDs 
have been proposed as an alternative solution to the standard needle injections, for 
the advantage of self-vaccination.
Further studies have been done to elucidate the interactions between polymers 
and vaccines, as in the case of hydrogel based MNs and dissolving MNs. In these 
cases, the antigen ovalbumin was used as a model protein interaction with polymers 
and the consequences on the immune response [40, 41].
Hollow MNs have the advantage of overcoming the skin barrier imposed by 
the stratum corneum and delivering bigger molecules, such as macromolecules or 
nanoparticle systems, in the fastest possible way. Polymeric nanoparticles encap-
sulating the model antigen ovalbumin have been intradermal delivered by means 
of hollow MNDs by Niu et al., reporting that this kind of delivery is a promising 
approach to improve the effectiveness of vaccine formulations [42]. Among the 
dissolving devices, MNs based on hyaluronic acid (HA) resulted a promising 
encapsulation method of high content of antigen molecules in intradermal  
vaccination [43].
Also anticancer drugs belong to an important field of application of MNDs: 
two research groups have investigated on DOX administration by means of MNs in 
[44] and in [45]. Nguyen et al. found in vitro studies that Polyvinyl Alcohol (PVA) 
MNs enhance the transdermal delivery of DOX. In an in vivo antitumor study of 
Hao et al., a near-infrared responsive PEGylated gold nanorod (GNR-PEG) and 
DOX-loaded dissolvable HA-based microneedle (GNR-PEG&DOX@HA MN) has 
been developed against cancer of epidermis. In the study, mice treated with GNR-
PEG&DOX@HA MNs taken remarkable advantage in antitumor efficacy in only 
one treatment, such that all mice have been cured without recurrence.
Moreover, lipophilic drugs found a lot of benefits from the use of MNs: poorly 
soluble drugs were encapsulated and easily administrated by MNDs, as in the case 
Biosensors - Current and Novel Strategies for Biosensing
8
Figure 4. 
Adapted with permission from ACS Appl. Polym. Mater. 2020, 2, 7, 2781–2790. Copyright (2020) American 
Chemical Society. Sketch of device and in vitro FITC-labeled insulin release at various temperatures, pH 7.4.
of the widely used specific 5-HT3 receptor antagonist, namely granisetron, that 
prevents nausea and vomiting during emetogenic chemotherapy in cancer patients 
[46]. In vivo results in [46] proved the evidence of controlled release systemic 
delivery.
An innovative pharmaceutical solution involving a MND in the field of HIV 
treatment has been proposed by Yavuz et al. in [47]. Also in this case, the self-
injection route of administration represents the key issue for care improvement, 
since it limited the risks of contamination of the personnel involved in therapy and 
guaranteed a painless delivery for the patients via patches of microneedles.
New drugs and innovative therapies have been put in place with the help of 
MNDs. In particular, polymeric MNs have been widely exploited for their porous 
nature, which is expressed both by soluble MNs and by simply biocompatible ones. 
In [48, 49], anti-obesity substances have been successfully administered. These 
substances modified the metabolic process by increasing the energy consumed and 
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transforming the white fat that stores calories into brown fat that burns calories 
[48]. While in [49], gelatin MNDs were used to induce lipolysis and suppress 
adipocyte lipogenesis in fatty rats.
Particular attention has to be paid on insulin delivery, since diabetes is one of 
the most common diseases, not only in elder patients, but also in obesity-affected 
patients.
Avoiding use of enzymes, a polymeric MND has been developed for on-demand 
insulin delivery by Chen et al. [50]. Continuous and acute glycemic control was 
realized with a long-acting, safe, stable, economically efficient and on-demand 
insulin delivery by MND, without depending on patient compliance. Thus, this 
technology opens to next generation of diabetes therapies.
In the same field, the treatment of individuals with type II diabetes mellitus has 
been successfully obtained with metformin HCl, the most widely used drug for this 
disease, delivered by means of hydrogel MNs [51].
In [52], authors proposed a temperature-independent MND for glucose-
responsive insulin release. The rapid and sustained regulation is enabled through 
a “skin layer” of Phenylboronic acid (PBA), formed on the surface of MNs. PBA 
is a synthetic hydrogel with reversible binding capability with glucose. Compared 
to other glucose-responsive MNDs based on nanoparticles or glucose oxidase, the 
proposed patch overcomes the safety concerns and provides a good sustainability 
for large-scale production. In Figure 4, a sketch of the proposed glucose-responsive 
Figure 5. 
The optical integrated MND presented in [6] have got a naked-eye monitor made up with a psi membrane to 
follow the release of a drug loaded in.
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insulin dispensing MND is presented together with main results in on-demand 
insulin release at physiological temperature.
Finally, we cite the engage of MNDs in effective administration of small pep-
tides, vitamin K and mRNA administered, both in vitro and in vivo studies [53–56].
In Table 1, main studies on therapeutic delivery with MNDs are summarized. 
Another important issue is the integration of MNs in optical, microelectronic or 
microfluidic devices. In [6], authors present the proof-of-concept of an optical inte-
grated MNDs based on polymeric MNs and porous silicon (PSi) for transdermal drug 
delivery (Figure 5). Since its surface can be chemically modified, PSi is one of the 
most popular porous material used in drug administration [57]. Moreover, PSi struc-
tures have a tunable refractive index that depends on their porosity [58]. The MND 
presented in [6] is based on PEGDA hydrogel MNs and includes a PSi free-standing 
membrane with a Bragg mirror optical structure, i.e. an optical structure that reflects 
a specific wavelength (color) in the visible spectrum. Furthermore, the Psi membrane 
not only acts as a drug/biomolecules reservoir, but also it can be used to optically 
monitor the released drug, since the reflected wavelength changes with the emptying 
of pores (Figure 5). In [6], the integrated-chip optical device guarantees the optimum 
disposable MND, which can be self-administrated and self-wasted, once the drug has 
been all delivered by only looking at the color variation at naked-eye.
4. Biosensing with microneedles
Human interstitial fluid (ISF) is on average between 9 and 13.5 L [59, 60]. Fluid 
moves from the lymphatic vasculature into the interstitium, among the endothelial 
MN type Disease Experiments Refs.
Swelling Acne vulgaris In vivo (mouse) [36]
Swelling Diabetes In vitro [50]
Swelling Diabetes In vivo (mouse) [51]
Swelling Immunity (vaccines) In vitro [40]
Swelling Nausea and vomiting In vivo [46]
Swelling Keloid scar Ex vivo [53]
Swelling/hybrid — in vitro [6]
Hollow Immunity (vaccines) — [42]
Dissolving Melasma In vivo (mouse) [35]
Dissolving Ocular infection Ex vivo (cornea) [37]
Dissolving Cancer In vitro [44]
Dissolving Cancer In vivo (mouse) [45, 54]
Dissolving Immunity (vaccines) In vivo (mouse) [41, 43]
Dissolving Obesity In vivo (mouse) [48, 49]
Dissolving Vitamin K deficiency In vitro [55]
Coated Warts In vivo (human) [34]
Coated Immunity (vaccines) In vivo (mouse) [39]
hybrid Diabetes In vivo (mouse) [52]
Table 1. 
Main studies on therapeutic delivery with MNDs. Adapted from [56].
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walls of cells, then to the blood plasma, and finally returns to the lymphatic vas-
culature. Analytes enter into the ISF through three paths: first, by transcellular 
path, through the capillaries; secondly, by paracellular path, through the cell walls; 
finally, by vesicular path, from the cells to the ISF [61, 62]. ISF moves within a net-
work of glycosaminoglycans, elastin, and collagen and transports electrolytes and 
metabolites to muscle cells, bone cells, cartilage, tissues, organs and so on [60, 63].
Dermal ISF is localized in the extracellular spaces between the vasculature, 
connective tissues and the cells. A lot of research efforts have been done to develop 
extraction methods of ISF in order to obtain an analytical composition and under-
stand the relationship between plasma and ISF. Table 2 summarizes the main 
ISF constituents, measured concentrations, and typical concentration ranges for 
healthy people [63].
Since its location just under human skin (the largest human organ) and its 
relationship with the vasculature system, analysis of ISF has received interest for 
the realization of new wearable devices.
On the other hand, new diagnostic methods can sensitively, rapidly and accu-
rately detect, analyze and monitor relevant diseases of social interest, and can lead 
to an effective management of healthcare. Biomarkers and biosensors research 
receive, then, a constantly increasing thrust.
Despite the transduction method used, innovation in standard sensing technolo-
gies is continuously pursued. Although several optical techniques, such as fluores-
cence, surface plasmon resonance and surface enhanced Raman spectroscopy have 
been exploited, electrochemical methods, based either on voltammetry or imped-
ance spectroscopy, have been demonstrated to quantify analytes in ISF with high 
sensitivity and easily integration into a MND [8].
Standard electrochemical sensors are realized confining bioprobes onto an 
electrode surface directly immersed in a solution, as the ISF. A key issue in the inno-
vation of electrochemical devices is the design of the so-called working electrode, 
that can increase the performance of the whole biosensor. The development of 
electrochemical engineered biosensors has been recently the focus of many research 
groups, which provided several fabrication strategies [64].
Electrochemical sensors based on MNs can analytically monitor biomarkers, 
drug release, metabolites, electrolytes and other chemical species present in dermal 
ISF and involved in biological functions. Recently, in [65] authors gave a proteomic 
characterization of the dermal ISF, extracted by means of a hollow MND. In this 
work, 407 proteins have been found and quantified [65]. Moreover, less than 1% 
of these proteins have been identified only into the ISF, confirming that the ISF is 







Cortisol 24–40 nM Morning: 1–50 nM Afternoon: 27–42 nM
Lactate 1.17 ± 0.23 mM 1–2 mM





Main ISF constituents, measured concentrations and typical concentration ranges for healthy people [63].
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invasive alternative devices to blood-derived fluids sensors with potential for 
real-time monitoring applications. In addition, in [66] an extremely small quantity 
(<1 nL) of the ISF was extracted by means of a hollow MN to measure drug concen-
trations and the typically painful blood drawn was avoided. In [66], the inner cavity 
of a hollow MN was derivatized to bind vancomycin. Optical absorbance is used 
as off-line transducer method, after extracting ISF with an integrated optofluidic 
device. The optofluidic MND detected the vancomycin in a sample volume of 0.6 nL 
with a limit of detection (LoD) of less than 100 nM.
Before being widely adopted into clinical practice, MNDs used as biosensors have 
to pursuit some general issues: a low cost fabrication; continuous monitoring and/
or long-lasting working time; the possibly of integration in MEMS; the protection of 
the bioprobe, critical in enzyme-based detection; a good electrical conductivity (EC) 
for electrochemical sensing [67]. Moreover, the biofouling at the tissue–device inter-
face must be avoided to successfully realize a wearable MND sensor [68]. According 
to Da Silva et al., currently, wearable sensors are still not yet ready for commercial 
develop, but within a few years MNDs biosensors will conquer the market [69].
In the field of MNDs for diagnostics, as well as for therapy, the approach can 
drastically vary with shapes and materials; Figure 1A shows a sketch of differ-
ent MNDs for sensing purposes together with their working conditions into the 
human skin. Starting from the right, Figure 6 reports: swelling bulk MNs sensors 
(BMNDs), whose diagnostic approach includes a volume effect in the probe-analyte 
interaction that will be considered separately; hollow MNs sensors (HMNDs), 
where a small material sampling of ISF is analyzed on or offline [70–72]; coated 
MNs sensors (CMNDs), whose surface is the locus of the interaction between 
analytes and bioprobes [73–81]; planar MNs sensors (PMNDs), where the probe–
analyte interaction is on a specific zone of a flat MNs surface [82].
The bulk volume of solid MNs (BMNDs) is often exploited in electrochemi-
cal biosensing. Usually, hydrogels and swelling polymers are employed in the 
fabrication of BMN. Examples are polyethylene glycol diacrylate (PEGDA), 
polyvinyl pyrrolidone (PVP), polyvinyl alcohol, poly(acrylic acid), poly-l-lactide, 
Figure 6. 
Design of the working electrode, optical images with and without metal coating and sketch of working of the 
MNDs. Experimental data for glucose and lactate acid dose–response. Reproduced with permission of Ref. [8]. 
PEGDA, polyethylene glycol diacrylate; FAD, flavin adenine dinucleotide.
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poly(lactide-coglycolide acid) and poly-N-isopropylacrylamide [83, 84]. These 
types of polymers can be processed by several fabrication techniques, such as rep-
lica molding, photolithography, drawing lithography and more [85]. Usually, probes 
and enhancers of transduction mechanisms are directly embedded in the porous 
polymer matrix during the fabrication. This environment protects probes without 
avoiding interaction between target analytes and bioprobes.
Caliò et al. trapped enzymes with vinyl-ferrocene mediator into a polymeric matrix 
of PEGDA in order to detect glucose and lactate exploiting the volume effect of the 
hydrogel matrix [27]. After being in contact with the ISF, the PEGDA matrix swells 
and the analytes solved into ISF enter the volume of the MNs, where a large number 
of probe molecules (enzymes) can be stored. The redox reaction takes place inside the 
volume and is transmitted to the electrode. The fabrication of the electrochemical MN 
biosensor only required a single further step (metal coating) in addition to the direct 
photolithographic process. The hybrid device traps GOx and LOX enzymes to enable 
the electrochemical detection of glucose and lactic acid, respectively, in physiological 
solution. The sensing MND showed a linear response from 0 to 4 mM for glucose, and 
from 0 to 1 mM for lactic acid (Figure 6) and a LoD of about 1 μM was found for both 
cases. Figure 6 shows design of the MN based working electrode, optical images with 
and without metal coating and a sketch of the working principle of the swelling MNDs. 
Moreover, experimental data for glucose and lactate acid dose–response are reported.
5. Conclusions
Appeared on scene as a painless alternative to syringes, MNDs have conquered 
the biomedicine. The flexibility of these innovative devices makes these techno-
logical platforms really attractive for even new fields of application. Almost all 
materials can be used in the fabrication of MNDs: noble metals (gold and silver), 
semiconductors (silicon), plastics (polymers and hydrogels), amorphous materi-
als (ceramics) and artificial nanostructured materials (porous silicon). MNDs 
have been used for drug delivery, cosmetic industry or biosensing, where the MN 
microstructures have been used as electrodes for electrochemical transduction. For 
biosensing systems, pros and cons have been highlighted for each device type in 
terms of analytical performances such as LoD, detection time, sensitivity and so on. 
In all the application cases, considerations about the safety of MNDs is due, since 
MNDs are conceived for being in contact with the human body. Then, inert, bio-
compatible, or physiologically dissolvable materials have to be engaged for device 
fabrication, even if they show lower analytical or delivery performances. After the 
overcoming of the skin natural barrier, MNs are directly in contact with human ISF. 
Hollow, coated, and swelling MNDs are all used in two ways: sensing of analytes 
and delivery of drugs; biosensing and administration; therapy and diagnosis.
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